Patent attributes
To provide a mutant Rad51 paralog gene, wherein a protein encoded thereby shows an activity for enhancing sensitivity of a cell to a DNA-damaging factor; a mutant Rad51 paralog peptide showing the activity; a transformed cell having the gene; a screening method for a drug having a DNA-damaging action, comprising contacting a test substance with the transformed cell, and evaluating a response of the cell; and a screening method for a controlling agent for DNA repair, comprising contacting a test substance with a transformed cell having the Rad51 paralog gene, and evaluating a homologous recombination repair capacity. According to the present invention, there is enabled a screening of a novel anticancer agent which allows a more efficient therapy for a cancer, wherein the agent is an agent capable of enhancing the sensitivity of a cell to an anticancer agent comprising a DNA-damaging factor or an agent having a DNA-damaging action.
